

3 **Furosemide**

4 **Injection, USP**

5 Rx only


6 **WARNING**

7 **Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a**
8 **profound diuresis with water and electrolyte depletion. Therefore, careful medical**
9 **supervision is required and dose and dose schedule must be adjusted to the individual**
10 **patient's needs (see DOSAGE AND ADMINISTRATION).**

11 **DESCRIPTION:**

12 Furosemide is a diuretic which is an anthranilic acid derivative. Chemically, it is 4-chloro-*N*-
13 furfuryl-5-sulfamoylanthranilic acid. Furosemide is a white to slightly yellow, odorless,
14 crystalline powder. Practically insoluble in water; freely soluble in acetone, in
15 dimethylformamide, and in solutions of alkali hydroxides; soluble in methanol; sparingly
16 soluble in alcohol; slightly soluble in ether; very slightly soluble in chloroform.

17 The structural formula is as follows:



18 **C₁₂H₁₁ClN₂O₅S**

M.W. 330.75

19

20

1 Furosemide Injection, USP is a sterile, nonpyrogenic solution of furosemide in Water for
2 Injection prepared with the aid of sodium hydroxide for intramuscular (IM) or intravenous (IV)
3 use.

4 Each mL contains: Furosemide 10 mg; Water for Injection q.s.; sodium chloride to adjust
5 isotonicity; sodium hydroxide and if necessary hydrochloric acid to adjust pH between 8.0 and
6 9.3.

7 **CLINICAL PHARMACOLOGY:**

8 Investigations into the mode of action of furosemide have utilized micropuncture studies in
9 rats, stop flow experiments in dogs and various clearance studies in both humans and
10 experimental animals. It has been demonstrated that furosemide inhibits primarily the
11 reabsorption of sodium and chloride not only in the proximal and distal tubules but also in the
12 loop of Henle. The high degree of efficacy is largely due to the unique site of action. The
13 action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and
14 aldosterone.

15 Recent evidence suggests that furosemide glucuronide is the only or at least the major
16 biotransformation product of furosemide in man. Furosemide is extensively bound to plasma
17 proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 mcg/mL are 91 to
18 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic
19 concentrations.

20 The onset of diuresis following IV administration is within five minutes and somewhat
21 later after IM administration. The peak effect occurs within the first half hour. The duration of
22 diuretic effect is approximately two hours.

23

1 In fasted normal men, the mean bioavailability of furosemide from tablets and oral
2 solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.
3 Although furosemide is more rapidly absorbed from the oral solution (50 minutes) than from
4 the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time
5 curves do not differ significantly. Peak plasma concentrations increase with increasing dose
6 but times-to-peak do not differ among doses. The terminal half-life of furosemide is
7 approximately two hours.

8 Significantly more furosemide is excreted in urine following the IV injection than after
9 the tablet or oral solution. There are no significant differences between the two oral
10 formulations in the amount of unchanged drug excreted in urine.

11 ***Geriatric Population***

12 Furosemide binding to albumin may be reduced in elderly patients. Furosemide is
13 predominantly excreted unchanged in the urine. The renal clearance of furosemide after
14 intravenous administration in older healthy male subjects (60 to 70 years of age) is statistically
15 significantly smaller than in younger healthy male subjects (20 to 35 years of age). The initial
16 diuretic effect of furosemide in older subjects is decreased relative to younger subjects (see
17 **PRECAUTIONS, *Geriatric Use***).

18 **INDICATIONS AND USAGE:**

19 Parenteral therapy should be reserved for patients unable to take oral medication or for patients
20 in emergency clinical situations.

21 ***Edema***

22 Furosemide is indicated in adults and pediatric patients for the treatment of edema associated
23 with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic

1 syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is
2 desired.

3 Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The IV
4 administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute
5 pulmonary edema.

6 If gastrointestinal absorption is impaired or oral medication is not practical for any
7 reason, furosemide is indicated by the IM or IV route. Parenteral use should be replaced with
8 oral furosemide as soon as practical.

9 **CONTRAINDICATIONS:**

10 Furosemide is contraindicated in patients with anuria and in patients with a history of
11 hypersensitivity to furosemide.

12 **WARNINGS:**

13 In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital.
14 In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the
15 basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with
16 cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the
17 period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist
18 are helpful in preventing hypokalemia and metabolic alkalosis.

19 If increasing azotemia and oliguria occur during treatment of severe progressive renal
20 disease, furosemide should be discontinued.

21 Cases of tinnitus and reversible or irreversible hearing impairment and deafness have
22 been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid
23 injection, severe renal impairment, the use of higher than recommended doses,

1 hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or
2 other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled
3 intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide
4 per minute has been used) (see **PRECAUTIONS, Drug Interactions**).

5 *Pediatric Use*

6 In premature neonates with respiratory distress syndrome, diuretic treatment with furosemide in
7 the first few weeks of life may increase the risk of persistent patent ductus arteriosus (PDA),
8 possibly through a prostaglandin-E-mediated process.

9 Literature reports indicate that premature infants with post conceptual age (gestational
10 plus postnatal) less than 31 weeks receiving doses exceeding 1 mg/kg/24 hours may develop
11 plasma levels which could be associated with potential toxic effects including ototoxicity.

12 Hearing loss in neonates has been associated with the use of furosemide injection (see
13 **WARNINGS**, above).

14 **PRECAUTIONS:**

15 *General*

16 Excessive diuresis may cause dehydration and blood volume reduction with circulatory
17 collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. As
18 with any effective diuretic, electrolyte depletion may occur during furosemide therapy,
19 especially in patients receiving higher doses and a restricted salt intake. Hypokalemia may
20 develop with furosemide, especially with brisk diuresis, inadequate oral electrolyte intake,
21 when cirrhosis is present, or during concomitant use of corticosteroids, ACTH, licorice in large
22 amounts, or prolonged use of laxatives. Digitalis therapy may exaggerate metabolic effects of
23 hypokalemia, especially myocardial effects.

1 All patients receiving furosemide therapy should be observed for these signs or
2 symptoms of fluid or electrolyte imbalance (hyponatremia, hypochloremic alkalosis,
3 hypokalemia, hypomagnesemia or hypocalcemia): dryness of mouth, thirst, weakness, lethargy,
4 drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria,
5 tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.
6 Increases in blood glucose and alterations in glucose tolerance tests (with abnormalities of the
7 fasting and two-hour postprandial sugar) have been observed, and rarely, precipitation of
8 diabetes mellitus has been reported.

9 In patients with severe symptoms of urinary retention (because of bladder emptying
10 disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can
11 cause acute urinary retention related to increased production and retention of urine. Thus, these
12 patients require careful monitoring, especially during the initial stages of treatment.

13 In patients at high risk for radiocontrast nephropathy, furosemide can lead to a higher
14 incidence of deterioration in renal function after receiving radiocontrast compared to high-risk
15 patients who received only intravenous hydration prior to receiving radiocontrast.

16 In patients with hypoproteinemia (e.g., associated with nephrotic syndrome) the effect
17 of furosemide may be weakened and its ototoxicity potentiated.

18 Asymptomatic hyperuricemia can occur and gout may rarely be precipitated.

19 Patients allergic to sulfonamides may also be allergic to furosemide. The possibility
20 exists of exacerbation or activation of systemic lupus erythematosus.

21 As with many other drugs, patients should be observed regularly for the possible
22 occurrence of blood dyscrasias, liver or kidney damage, or other idiosyncratic reactions.

23

1 ***Information for Patients***

2 Patients receiving furosemide should be advised that they may experience symptoms from
3 excessive fluid and/or electrolyte losses. The postural hypotension that sometimes occurs can
4 usually be managed by getting up slowly. Potassium supplements and/or dietary measures may
5 be needed to control or avoid hypokalemia.

6 Patients with diabetes mellitus should be told that furosemide may increase blood
7 glucose levels and thereby affect urine glucose tests. The skin of some patients may be more
8 sensitive to the effects of sunlight while taking furosemide.

9 Hypertensive patients should avoid medications that may increase blood pressure,
10 including over-the-counter products for appetite suppression and cold symptoms.

11 ***Laboratory Tests***

12 Serum electrolytes (particularly potassium), CO₂, creatinine and BUN should be determined
13 frequently during the first few months of furosemide therapy and periodically thereafter.

14 Serum and urine electrolyte determinations are particularly important when the patient is
15 vomiting profusely or receiving parenteral fluids. Abnormalities should be corrected or the
16 drug temporarily withdrawn. Other medications may also influence serum electrolytes.

17 Reversible elevations of BUN may occur and are associated with dehydration, which
18 should be avoided, particularly in patients with renal insufficiency.

19 Urine and blood glucose should be checked periodically in diabetics receiving
20 furosemide, even in those suspected of latent diabetes.

21 Furosemide may lower serum levels of calcium (rarely cases of tetany have been
22 reported) and magnesium. Accordingly, serum levels of these electrolytes should be
23 determined periodically.

1 In premature infants furosemide may precipitate nephrocalcinosis/nephrolithiasis,
2 therefore renal function must be monitored and renal ultrasonography performed (see
3 **PRECAUTIONS, *Pediatric Use***).

4 ***Drug Interactions***

5 Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the
6 presence of impaired renal function. Except in life-threatening situations, avoid this
7 combination.

8 Furosemide should not be used concomitantly with ethacrynic acid because of the
9 possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with
10 furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because
11 of competitive renal excretory sites.

12 There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly.
13 In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if
14 furosemide is not given in lower doses and with positive fluid balance when used to achieve
15 forced diuresis during cisplatin treatment.

16 Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of
17 tubocurarine and may potentiate the action of succinylcholine.

18 Lithium generally should not be given with diuretics because they reduce lithium's
19 renal clearance and add a high risk of lithium toxicity.

20 Furosemide combined with angiotensin converting enzyme inhibitors or angiotensin II
21 receptor blockers may lead to severe hypotension and deterioration in renal function, including
22 renal failure. An interruption or reduction in the dosage of furosemide, angiotensin converting
23 enzyme inhibitors, or angiotensin receptor blockers may be necessary.

1 Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

2 Furosemide may decrease arterial responsiveness to norepinephrine. However,
3 norepinephrine may still be used effectively.

4 Simultaneous administration of sucralfate and Furosemide Injection may reduce the
5 natriuretic and antihypertensive effects of furosemide. Patients receiving both drugs should be
6 observed closely to determine if the desired diuretic and/or antihypertensive effect of
7 furosemide is achieved. The intake of furosemide and sucralfate should be separated by at least
8 two hours.

9 In isolated cases, intravenous administration of furosemide within 24 hours of taking
10 chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood
11 pressure, and tachycardia. Use of furosemide concomitantly with chloral hydrate is therefore
12 not recommended.

13 Phenytoin interferes directly with renal action of furosemide. There is evidence that
14 treatment with phenytoin leads to decrease intestinal absorption of furosemide, and
15 consequently to lower peak serum furosemide concentrations.

16 Methotrexate and other drugs that, like furosemide, undergo significant renal tubular
17 secretion may reduce the effect of furosemide. Conversely, furosemide may decrease renal
18 elimination of other drugs that undergo tubular secretion. High-dose treatment of both
19 furosemide and these other drugs may result in elevated serum levels of these drugs and may
20 potentiate their toxicity as well as the toxicity of furosemide.

21 Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the
22 setting of minor or transient renal impairment.

23

1 Concomitant use of cyclosporine and furosemide is associated with increased risk of
2 gouty arthritis secondary to furosemide-induced hyperurecemia and cyclosporine impairment
3 of renal urate excretion.

4 High doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to
5 carrier proteins and result in transient increase in free thyroid hormones, followed by an overall
6 decrease in total thyroid hormone levels.

7 One study in six subjects demonstrated that the combination of furosemide and
8 acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal
9 insufficiency. There are case reports of patients who developed increased BUN, serum
10 creatinine and serum potassium levels, and weight gain when furosemide was used in
11 conjunction with NSAIDs.

12 Literature reports indicate that coadministration of indomethacin may reduce the
13 natriuretic and antihypertensive effects of furosemide in some patients by inhibiting
14 prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone
15 excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide
16 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of
17 furosemide is achieved.

18 ***Carcinogenesis, Mutagenesis, Impairment of Fertility***

19 Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one
20 strain of rats. A small but significantly increased incidence of mammary gland carcinomas
21 occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg. There were
22 marginal increases in uncommon tumors in male rats at a dose of 15 mg/kg (slightly greater
23 than the maximum human dose) but not at 30 mg/kg.

1 Furosemide was devoid of mutagenic activity in various strains of *Salmonella*
2 *typhimurium* when tested in the presence or absence of an *in vitro* metabolic activation system,
3 and questionably positive for gene mutation in mouse lymphoma cells in the presence of rat
4 liver S9 at the highest dose tested. Furosemide did not induce sister chromatid exchange in
5 human cells *in vitro*, but other studies on chromosomal aberrations in human cells *in vitro* gave
6 conflicting results. In Chinese hamster cells it induced chromosomal damage but was
7 questionably positive for sister chromatid exchange. Studies on the induction by furosemide of
8 chromosomal aberrations in mice were inconclusive. The urine of rats treated with this drug
9 did not induce gene conversion in *Saccharomyces cerevisiae*.

10 Furosemide produced no impairment of fertility in male or female rats, at 100 mg/kg/day
11 (the maximum effective diuretic dose in the rat and 8 times the maximal human dose of
12 600 mg/day).

13 ***Pregnancy—Teratogenic Effects***

14 *Pregnancy Category C*—Furosemide has been shown to cause unexplained maternal deaths
15 and abortions in rabbits at two, four and eight times the maximal recommended human oral
16 dose. There are no adequate and well-controlled studies in pregnant women. Furosemide
17 should be used during pregnancy only if the potential benefit justifies the potential risk to the
18 fetus.

19 Treatment during pregnancy requires monitoring of fetal growth because of the potential
20 for higher fetal birth weights.

21 The effects of furosemide on embryonic and fetal development and on pregnant dams
22 were studied in mice, rats and rabbits.

23 Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest

1 dose of 25 mg/kg (two times the maximal recommended human oral dose of 600 mg/day). In
2 another study, a dose of 50 mg/kg (four times the maximal recommended human oral dose of
3 600 mg/day) also caused maternal deaths and abortions when administered to rabbits between
4 Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived an oral
5 dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede
6 maternal deaths.

7 The results of the mouse study and one of the three rabbit studies also showed an
8 increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some
9 cases, of the ureters) in fetuses derived from treated dams as compared with the incidence in
10 fetuses from the control group.

11 *Nursing Mothers*

12 Because it appears in breast milk, caution should be exercised when furosemide is administered
13 to a nursing mother. Furosemide may inhibit lactation.

14 *Pediatric Use*

15 Renal calcifications (from barely visible on x-ray to staghorn) have occurred in some severely
16 premature infants treated with IV furosemide for edema due to patent ductus arteriosus and
17 hyaline membrane disease. The concurrent use of chlorothiazide has been reported to decrease
18 hypercalcinuria and dissolve some calculi.

19 In premature infants furosemide may precipitate nephrocalcinosis/nephrolithiasis.
20 Nephrocalcinosis/nephrolithiasis has also been observed in children under 4 years of age with
21 no history of prematurity who have been treated chronically with furosemide. Monitor renal
22 function, and renal ultrasonography should be considered, in pediatric patients receiving
23 furosemide.

1 If furosemide is administered to premature infants during the first weeks of life, it may
2 increase the risk of persistence of patent ductus arteriosus.

3

4 ***Geriatric Use***

5 Controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65
6 and over to determine whether they respond differently from younger subjects. Other reported
7 clinical experience has not identified differences in responses between the elderly and younger
8 patients. In general, dose selection for the elderly patient should be cautious, usually starting at
9 the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or
10 cardiac function, and of concomitant disease or other drug therapy.

11 This drug is known to be substantially excreted by the kidney, and the risk of toxic
12 reactions to this drug may be greater in patients with impaired renal function. Because elderly
13 patients are more likely to have decreased renal function, care should be taken in dose selection
14 and it may be useful to monitor renal function (see **PRECAUTIONS, *General*** and **DOSAGE
15 AND ADMINISTRATION**).

16 **ADVERSE REACTIONS:**

17 Adverse reactions are categorized below by organ system and listed by decreasing severity.

18 ***Gastrointestinal System Reactions***

- 19 1. Hepatic encephalopathy in patients with hepatocellular insufficiency
- 20 2. Pancreatitis
- 21 3. Jaundice (intrahepatic cholestatic jaundice)
- 22 4. Increased liver enzymes
- 23 5. Anorexia

1 6. Oral and gastric irritation

2 7. Cramping

3 8. Diarrhea

4 9. Constipation

5 10. Nausea

6 11. Vomiting

7 ***Systemic Hypersensitivity Reactions***

8 1. Severe anaphylactic or anaphylactoid reactions (e.g., with shock)

9 2. Systemic vasculitis

10 3. Interstitial nephritis

11 4. Necrotizing angiitis

12 ***Central Nervous System Reactions***

13 1. Tinnitus and hearing loss

14 2. Paresthesias

15 3. Vertigo

16 4. Dizziness

17 5. Headache

18 6. Blurred vision

19 7. Xanthopsia

20 ***Hematologic Reactions***

21 1. Aplastic anemia

22 2. Thrombocytopenia

23 3. Agranulocytosis

- 1 4. Hemolytic anemia
- 2 5. Leukopenia
- 3 6. Anemia
- 4 7. Eosinophilia

5 ***Dermatologic-Hypersensitivity Reactions***

- 6 1. Toxic epidermal necrolysis
- 7 2. Stevens-Johnson Syndrome
- 8 3. Erythema multiforme
- 9 4. Drug rash with eosinophila and systemic symptoms
- 10 5. Acute generalized exanthematous pustulosis
- 11 6. Exfoliative dermatitis
- 12 7. Bullous pemphigoid
- 13 8. Purpura
- 14 9. Photosensitivity
- 15 10. Rash
- 16 11. Pruritus
- 17 12. Urticaria

18 ***Cardiovascular Reactions***

- 19 1. Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or
- 20 narcotics
- 21 2. Increase in cholesterol and triglyceride serum levels

22 ***Other Reactions***

- 23 1. Hyperglycemia

- 1 2. Glycosuria
- 2 3. Hyperuricemia
- 3 4. Muscle spasm
- 4 5. Weakness
- 5 6. Restlessness
- 6 7. Urinary bladder spasm
- 7 8. Thrombophlebitis
- 8 9. Transient injection site pain following intramuscular injection
- 9 10. Fever

10 Whenever adverse reactions are moderate or severe, furosemide dosage should be
11 reduced or therapy withdrawn.

12 **OVERDOSAGE:**

13 The principal signs and symptoms of overdose with furosemide are dehydration, blood volume
14 reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and
15 are extensions of its diuretic action.

16 The acute toxicity of furosemide has been determined in mice, rats and dogs. In all
17 three, the oral LD₅₀ exceeded 1,000 mg/kg body weight, while the intravenous LD₅₀ ranged
18 from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of
19 adult rats.

20 The concentration of furosemide in biological fluids associated with toxicity or death is
21 not known.

22 Treatment of overdosage is supportive and consists of replacement of excessive fluid
23 and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be

1 determined frequently. Adequate drainage must be assured in patients with urinary bladder
2 outlet obstruction (such as prostatic hypertrophy).

3 Hemodialysis does not accelerate furosemide elimination.

4

1 **DOSAGE AND ADMINISTRATION:**

2 *Adults*

3 Parenteral therapy with furosemide injection should be used only in patients unable to take oral
4 medication or in emergency situations and should be replaced with oral therapy as soon as
5 practical.

6 *Edema*—The usual initial dose of furosemide is 20 to 40 mg given as a single dose, injected IM
7 or IV. The IV dose should be given slowly (one to two minutes). Ordinarily a prompt diuresis
8 ensues. If needed, another dose may be administered in the same manner two hours later or the
9 dose may be increased. The dose may be raised by 20 mg and given not sooner than two hours
10 after the previous dose until the desired diuretic effect has been obtained. This individually
11 determined single dose should then be given once or twice daily.

12 Therapy should be individualized according to patient response to gain maximal
13 therapeutic response and to determine the minimal dose needed to maintain that response.
14 Close medical supervision is necessary.

15 If the physician elects to use high dose parenteral therapy, add the furosemide to either
16 Sodium Chloride Injection USP, Lactated Ringer's Injection USP, or Dextrose Injection 5%
17 USP, after pH has been adjusted to above 5.5, and administer as a controlled IV infusion at a
18 rate not greater than 4 mg/min. Furosemide injection is a buffered alkaline solution with a pH
19 of about 9 and the drug may precipitate at pH values below 7. Care must be taken to ensure
20 that the pH of the prepared infusion solution is in the weakly alkaline to neutral range. Acid
21 solutions, including other parenteral medications (e.g., labetalol, ciprofloxacin, amrinone,
22 milrinone) must not be administered concurrently in the same infusion because they may cause
23 precipitation of the furosemide. In addition, furosemide injection should not be added to a

1 running intravenous line containing any of these acidic products.

2 ***Acute Pulmonary Edema***—The usual initial dose of furosemide is 40 mg injected slowly IV
3 (over one to two minutes). If a satisfactory response does not occur within one hour, the dose
4 may be increased to 80 mg injected slowly IV (over one to two minutes).

5 If necessary, additional therapy (e.g., digitalis, oxygen) may be administered
6 concomitantly.

7 ***Geriatric Patients***

8 In general, dose selection for the elderly patient should be cautious, usually starting at the low
9 end of the dosing range (see **PRECAUTIONS, *Geriatric Use***).

10 ***Pediatric Patients***

11 Parenteral therapy should be used only in patients unable to take oral medication or in
12 emergency situations and should be replaced with oral therapy as soon as practical.

13 The usual initial dose of furosemide injection (IM or IV) in pediatric patients is 1 mg/kg
14 body weight and should be given slowly under close medical supervision. If the diuretic
15 response to the initial dose is not satisfactory, dosage may be increased by 1 mg/kg not sooner
16 than two hours after the previous dose, until the desired diuretic effect has been obtained.
17 Doses greater than 6 mg/kg body weight are not recommended.

18 Literature reports suggest that the maximum dose for premature infants should not
19 exceed 1 mg/kg/day (see **WARNINGS, *Pediatric Use***).

20 Furosemide injection should be inspected visually for particulate matter and
21 discoloration before administration. Do not use if solution is discolored.

22

1 **HOW SUPPLIED:**

2 Furosemide injection, USP

Product No.	NDC No.	Strength	Volume
28002	63323-280-02	20 mg per 2 mL (10 mg per mL)	2 mL in a 2 mL amber vial.
28004	63323-280-04	40 mg per 4 mL (10 mg per mL)	4 mL in a 5 mL amber vial.
28010	63323-280-10	100 mg per 10 mL (10 mg per mL)	10 mL in a 10 mL amber vial.

3

4 2 mL, 4 mL and 10 mL sizes are single use vials, packaged 25 vials per tray.

5 **Preservative Free.** Discard unused portion.

6 Use only if solution is clear and seal intact.

7 **PROTECT FROM LIGHT.** Do not use if solution is discolored.

8 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

9



10

11 www.fresenius-kabi.us

12 45788E

13 Revised: March 2016